Royalty Pharma plc RPRX

RPRX Company Overview

Royalty Pharma plc is a biopharmaceutical royalty acquisition company focused on funding innovation in the life sciences industry. The company acquires, funds, and manages royalties and other revenue interests tied to approved and development-stage biopharmaceutical products. It operates primarily within the biotechnology, pharmaceutical financing, and healthcare investment sectors, serving pharmaceutical companies, biotechnology firms, academic institutions, and research hospitals. Royalty Pharma’s core revenue drivers are royalty payments generated from sales of marketed therapies across oncology, rare disease, neuroscience, immunology, hematology, and infectious disease categories.

The company is widely recognized for its specialized model of providing non-dilutive capital to drug developers and research institutions in exchange for future royalty streams. Its portfolio includes royalties on products such as Tremfya, Imbruvica, Xtandi, Evrysdi, Trodelvy, and cystic fibrosis therapies developed by Vertex Pharmaceuticals. Royalty Pharma was founded in 1996 by Pablo Legorreta and evolved from a niche royalty investor into one of the largest buyers of biopharmaceutical royalties globally. The company completed its public listing on Nasdaq in 2020 under the ticker RPRX.